These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 26987494)

  • 1. Clinical relevance of high sensitivity C-reactive protein in cardiology.
    Adukauskienė D; Čiginskienė A; Adukauskaitė A; Pentiokinienė D; Šlapikas R; Čeponienė I
    Medicina (Kaunas); 2016; 52(1):1-10. PubMed ID: 26987494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Correlation of high-sensitivity CRP concentration with the extent of coronary atherosclerosis in men with symptoms of ischemic heart disease].
    Piechota W; Piechota W
    Pol Merkur Lekarski; 2005 May; 18(107):511-5. PubMed ID: 16161944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels.
    Carter NJ
    Am J Cardiovasc Drugs; 2010; 10(6):383-400. PubMed ID: 21090831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Use of High Sensitivity C-Reactive Protein in Cardiovascular Disease Detection.
    Castro AR; Silva SO; Soares SC
    J Pharm Pharm Sci; 2018; 21(1):496-503. PubMed ID: 30496036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. C-reactive protein: a nontraditional serum marker of cardiovascular risk.
    de Ferranti SD; Rifai N
    Cardiovasc Pathol; 2007; 16(1):14-21. PubMed ID: 17218210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus.
    Pfützner A; Forst T
    Diabetes Technol Ther; 2006 Feb; 8(1):28-36. PubMed ID: 16472048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM; Silvertown JD
    J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association of albuminuria and high-sensitivity C-reactive protein with the efficacy of HMG-coenzyme A reductase inhibitors for cardiovascular event prevention.
    Özyilmaz A; Boersma C; Visser ST; Postma MJ; de Jong-van den Berg LT; Lambers-Heerspink HJ; de Jong PE; Gansevoort RT
    Eur J Prev Cardiol; 2016 May; 23(8):847-55. PubMed ID: 26358992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trials investigating the relationship between dietary pattern and high-sensitivity C-reactive protein: a systematic review.
    Pickworth CK; Deichert DA; Corroon J; Bradley RD
    Nutr Rev; 2019 Jun; 77(6):363-375. PubMed ID: 31222367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Sensitivity C-reactive Protein (hsCRP) and its Implications in Cardiovascular Outcomes.
    Denegri A; Boriani G
    Curr Pharm Des; 2021; 27(2):263-275. PubMed ID: 32679014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High sensitivity C-reactive protein in cardiovascular risk assessment. CRP mania or useful screening?
    Sellmayer A; Limmert T; Hoffmann U
    Int Angiol; 2003 Mar; 22(1):15-23. PubMed ID: 12771851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations between cardiovascular disease risk factors and IL-6 and hsCRP levels in the elderly.
    Nadrowski P; Chudek J; Skrzypek M; Puzianowska-Kuźnicka M; Mossakowska M; Więcek A; Zdrojewski T; Grodzicki T; Kozakiewicz K
    Exp Gerontol; 2016 Dec; 85():112-117. PubMed ID: 27729238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.
    Ridker PM
    J Am Coll Cardiol; 2007 May; 49(21):2129-38. PubMed ID: 17531663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
    Koenig W
    Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An overview of inflammatory markers in type 2 diabetes from the perspective of the clinical chemist.
    Kimberly MM; Cooper GR; Myers GL
    Diabetes Technol Ther; 2006 Feb; 8(1):37-44. PubMed ID: 16472049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
    Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
    Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG; Zacho J
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events.
    Vainas T; Stassen FR; de Graaf R; Twiss EL; Herngreen SB; Welten RJ; van den Akker LH; van Dieijen-Visser MP; Bruggeman CA; Kitslaar PJ
    J Vasc Surg; 2005 Aug; 42(2):243-51. PubMed ID: 16102622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CRP--a marker of a pro-inflammatory state and cardiovascular risk].
    Poledne R; Valenta Z; Pit'ha J
    Vnitr Lek; 2007 Apr; 53(4):391-5. PubMed ID: 17578172
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.